← Turn Therapeutics Inc. (TTRX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Turn Therapeutics Inc. (TTRX)
Pharmaceutical Preparations · market cap $446M · as of 2026-07-13
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-12 (est.)
Earnings
Pipeline
1
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Turn Therapeutics Inc. (TTRX) is a micro-cap pharmaceutical company with 2 employees and a market cap of ~$281M, trading at ~$9.44 per share. Its sole disclosed asset is GX-03, a Phase 2 compound targeting COVID-19 with an undisclosed mechanism. Financials are thin: $11M cash, ~20 months of runway, and essentially no revenue in 2025.
The catalyst path
- 2026-11-12 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| GX-03 | Phase 2 | Covid19 |
Price & technical context
3-month
+86.9%
6-month
+326.6%
12-month
—
52-wk range
$2.71–$15.34
vs 50-day MA
+21.5%
vs 200-day MA
+113.5%
Realized vol
107.8%
Max drawdown
-70.5%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for TTRX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.